Posted by Michael Wonder on 13 Nov 2020
Angelini Pharma and Sunovion Pharmaceutical Europe receive EMA approval for Latuda, first atypical antipsychotic for the treatment of adolescent schizophrenia in patients starting from 13 years of age
12 November 2020 - Angelini Pharma and Sunovion Pharmaceutical Europe announced today the EMA approval for Latuda (lurasidone), with the indication for the treatment of adolescent schizophrenia in patients starting from 13 years of age.
Latuda becomes the first second generation antipsychotic to be approved for patients suffering from schizophrenia as young as 13 years of age.
In addition to the new indication, Latuda was also granted an additional year of marketing protection.
